Capmatinib Granted Regular Approval for Metastatic Non–Small Cell Lung Cancer

The FDA has granted regular approval to capmatinib (Tabrecta®, Novartis Pharmaceuticals Corp.) for treatment of adult patients with metastatic non–small cell lung cancer (NSCLC) who have tumors evolving into the mesenchymal-epithelial transition exon 14 skipping (METex14) mutation. Capmatinib was previously granted accelerated approval in May 2020 based on initial data from the GEOMETRY mono-1 trial (NCT02414139); due to updated results, the FDA is now converting it to regular approval. "Activat...

Continue reading

New Treatment Targets Chemotherapy-Resistant Brain Cancer

Researchers have demonstrated the efficacy of a new treatment targeting genetic mutations in patients with chemotherapy-resistant secondary glioblastoma (sGBM), a rare and deadly form of brain cancer. Low-grade gliomas progress into sGBM, which has limited treatment options and a 5-year survival rate under 10%. Secondary glioblastoma is treated with temozolomide (TMZ), a chemotherapy drug. Upon relapse, which happens in most patients, genetic mutations enable sGBM tumors to resist the drug's eff...

Continue reading

Copyright © 2022 Oncology Data Advisor. All rights reserved.